Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy

Seon Ah Lim, Tae Jin Kim, Jung Eun Lee, Chung Hee Sonn, Kwanghee Kim, Jiyoung Kim, Jong Gwon Choi, Il Kyu Choi, Chae Ok Yun, Jae-Hong Kim, Cassian Yee, Vinay Kumar, Kyung-Mi Lee

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Adoptive natural killer (NK) cell therapy may offer an effective treatment regimen for cancer patients whose disease is refractory to conventional therapy. NKcells can kill a wide range of tumor cells by patterned recognition of target ligands. We hypothesized that tumor targets sensitive to NK lysis would drive vigorous expansion of NK cells from human peripheral blood mononuclear cells (PBMC). Here, we provide the basis for developing a novel ex vivo expansion process. By screening class I-negative or -mismatched tumor cell lines we identified a Jurkat Tlymphoblast subline termed KL-1, which was highly effective in specifically expanding NK cells. KL-1 addition to PBMC cultures achieved approximately 100-fold expansion of NK cells with nearly 90% purity, accompanied by reciprocal inhibition of T-cell growth. Marked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models. KL-1-mediated expansion of NK cells was contact dependent and required interactions with CD16, the Fcg receptor on NK cells, with ligands that are expressed on B cells. Indeed, B-cell depletion during culture abrogated selective NK cell expansion, while addition of EBV-transformed B cells further augmented NK expansion to approximately 740-fold. Together, our studies define a novel method for efficient activation of human NK cells that employs KL-1-lysed tumor cells and cocultured B cells, which drive a robust expansion of potent antitumor effector cells that will be useful for clinical evaluation.

Original languageEnglish
Pages (from-to)2598-2607
Number of pages10
JournalCancer Research
Volume73
Issue number8
DOIs
Publication statusPublished - 2013 Apr 15

Fingerprint

Adoptive Immunotherapy
Coculture Techniques
Natural Killer Cells
B-Lymphocytes
Neoplasms
Natural Cytotoxicity Triggering Receptor 2
Natural Cytotoxicity Triggering Receptor 3
Blood Cells
Natural Killer Cell Receptors
Ligands
Intercellular Adhesion Molecule-1
Cell- and Tissue-Based Therapy
Tumor Cell Line
Human Herpesvirus 4
Cell Culture Techniques
T-Lymphocytes
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. / Lim, Seon Ah; Kim, Tae Jin; Lee, Jung Eun; Sonn, Chung Hee; Kim, Kwanghee; Kim, Jiyoung; Choi, Jong Gwon; Choi, Il Kyu; Yun, Chae Ok; Kim, Jae-Hong; Yee, Cassian; Kumar, Vinay; Lee, Kyung-Mi.

In: Cancer Research, Vol. 73, No. 8, 15.04.2013, p. 2598-2607.

Research output: Contribution to journalArticle

Lim, SA, Kim, TJ, Lee, JE, Sonn, CH, Kim, K, Kim, J, Choi, JG, Choi, IK, Yun, CO, Kim, J-H, Yee, C, Kumar, V & Lee, K-M 2013, 'Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy', Cancer Research, vol. 73, no. 8, pp. 2598-2607. https://doi.org/10.1158/0008-5472.CAN-12-2893
Lim, Seon Ah ; Kim, Tae Jin ; Lee, Jung Eun ; Sonn, Chung Hee ; Kim, Kwanghee ; Kim, Jiyoung ; Choi, Jong Gwon ; Choi, Il Kyu ; Yun, Chae Ok ; Kim, Jae-Hong ; Yee, Cassian ; Kumar, Vinay ; Lee, Kyung-Mi. / Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. In: Cancer Research. 2013 ; Vol. 73, No. 8. pp. 2598-2607.
@article{9fd1d12d484149e0859136d4b743c2af,
title = "Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy",
abstract = "Adoptive natural killer (NK) cell therapy may offer an effective treatment regimen for cancer patients whose disease is refractory to conventional therapy. NKcells can kill a wide range of tumor cells by patterned recognition of target ligands. We hypothesized that tumor targets sensitive to NK lysis would drive vigorous expansion of NK cells from human peripheral blood mononuclear cells (PBMC). Here, we provide the basis for developing a novel ex vivo expansion process. By screening class I-negative or -mismatched tumor cell lines we identified a Jurkat Tlymphoblast subline termed KL-1, which was highly effective in specifically expanding NK cells. KL-1 addition to PBMC cultures achieved approximately 100-fold expansion of NK cells with nearly 90{\%} purity, accompanied by reciprocal inhibition of T-cell growth. Marked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models. KL-1-mediated expansion of NK cells was contact dependent and required interactions with CD16, the Fcg receptor on NK cells, with ligands that are expressed on B cells. Indeed, B-cell depletion during culture abrogated selective NK cell expansion, while addition of EBV-transformed B cells further augmented NK expansion to approximately 740-fold. Together, our studies define a novel method for efficient activation of human NK cells that employs KL-1-lysed tumor cells and cocultured B cells, which drive a robust expansion of potent antitumor effector cells that will be useful for clinical evaluation.",
author = "Lim, {Seon Ah} and Kim, {Tae Jin} and Lee, {Jung Eun} and Sonn, {Chung Hee} and Kwanghee Kim and Jiyoung Kim and Choi, {Jong Gwon} and Choi, {Il Kyu} and Yun, {Chae Ok} and Jae-Hong Kim and Cassian Yee and Vinay Kumar and Kyung-Mi Lee",
year = "2013",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-12-2893",
language = "English",
volume = "73",
pages = "2598--2607",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy

AU - Lim, Seon Ah

AU - Kim, Tae Jin

AU - Lee, Jung Eun

AU - Sonn, Chung Hee

AU - Kim, Kwanghee

AU - Kim, Jiyoung

AU - Choi, Jong Gwon

AU - Choi, Il Kyu

AU - Yun, Chae Ok

AU - Kim, Jae-Hong

AU - Yee, Cassian

AU - Kumar, Vinay

AU - Lee, Kyung-Mi

PY - 2013/4/15

Y1 - 2013/4/15

N2 - Adoptive natural killer (NK) cell therapy may offer an effective treatment regimen for cancer patients whose disease is refractory to conventional therapy. NKcells can kill a wide range of tumor cells by patterned recognition of target ligands. We hypothesized that tumor targets sensitive to NK lysis would drive vigorous expansion of NK cells from human peripheral blood mononuclear cells (PBMC). Here, we provide the basis for developing a novel ex vivo expansion process. By screening class I-negative or -mismatched tumor cell lines we identified a Jurkat Tlymphoblast subline termed KL-1, which was highly effective in specifically expanding NK cells. KL-1 addition to PBMC cultures achieved approximately 100-fold expansion of NK cells with nearly 90% purity, accompanied by reciprocal inhibition of T-cell growth. Marked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models. KL-1-mediated expansion of NK cells was contact dependent and required interactions with CD16, the Fcg receptor on NK cells, with ligands that are expressed on B cells. Indeed, B-cell depletion during culture abrogated selective NK cell expansion, while addition of EBV-transformed B cells further augmented NK expansion to approximately 740-fold. Together, our studies define a novel method for efficient activation of human NK cells that employs KL-1-lysed tumor cells and cocultured B cells, which drive a robust expansion of potent antitumor effector cells that will be useful for clinical evaluation.

AB - Adoptive natural killer (NK) cell therapy may offer an effective treatment regimen for cancer patients whose disease is refractory to conventional therapy. NKcells can kill a wide range of tumor cells by patterned recognition of target ligands. We hypothesized that tumor targets sensitive to NK lysis would drive vigorous expansion of NK cells from human peripheral blood mononuclear cells (PBMC). Here, we provide the basis for developing a novel ex vivo expansion process. By screening class I-negative or -mismatched tumor cell lines we identified a Jurkat Tlymphoblast subline termed KL-1, which was highly effective in specifically expanding NK cells. KL-1 addition to PBMC cultures achieved approximately 100-fold expansion of NK cells with nearly 90% purity, accompanied by reciprocal inhibition of T-cell growth. Marked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models. KL-1-mediated expansion of NK cells was contact dependent and required interactions with CD16, the Fcg receptor on NK cells, with ligands that are expressed on B cells. Indeed, B-cell depletion during culture abrogated selective NK cell expansion, while addition of EBV-transformed B cells further augmented NK expansion to approximately 740-fold. Together, our studies define a novel method for efficient activation of human NK cells that employs KL-1-lysed tumor cells and cocultured B cells, which drive a robust expansion of potent antitumor effector cells that will be useful for clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=84876887378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876887378&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-2893

DO - 10.1158/0008-5472.CAN-12-2893

M3 - Article

VL - 73

SP - 2598

EP - 2607

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8

ER -